Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates
Jie Fang(Chinese Academy of Sciences), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Richard J. Colonno(Assembly Biosciences (United States)), Michael Wichroski(Bristol-Myers Squibb (Germany)), Bernadette Kienzle(Bristol-Myers Squibb (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Carl J. Baldick(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Ann W. Walsh(Bristol-Myers Squibb (United States))
Cited by 12
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239